Massive Bio Nominated for Prestigious Digital Health Award


Massive Bio has been named a Best in Class Quarterfinalist within the UCSF | Health Hub: Digital Health Awards competitors.

NEW YORK CITY, NY, USA, October 6, 2022 / — Massive Bio has been named a quarterfinalist within the annual UCSF | Health Hub: Digital Health Awards, recognizing well being tech firms driving innovation and bettering healthcare supply.

Massive Bio has been named a Best in Class Quarterfinalist within the UCSF | Health Hub: Digital Health Awards competitors. These prestigious awards are granted yearly by UCSF Health Hub (a non-profit group affiliated with the University of California San Francisco) to acknowledge “the achievements of innovative health tech companies that are dramatically improving healthcare through the use of technology in the digital health industry.”

More than 1,250 firms entered this 12 months’s UCSF | Health Hub: Digital Health Awards competitors. Massive Bio was chosen by a panel of over 1,000 consultants from {industry} and academia as certainly one of 16 quarterfinalists within the “New Health Application of AI” class, which honors excellence in utilizing synthetic intelligence to enhance the standard, reliability, and cost-efficiency of healthcare. Massive Bio’s distinctive synthetic intelligence-driven platform, SYNERGY-AI, quickly matches most cancers sufferers to scientific trials of promising new oncology therapies. The firm’s mission is to take away obstacles to scientific trials for sufferers needing superior therapies and improve the effectivity of drug growth for the pharmaceutical {industry}.

“This nomination represents an important milestone for Massive Bio, being recognized as a major player in the digital health space at a global level, and we are honored and humbled to be listed amongst the ‘best in class in the industry,” stated Arturo Loaiza-Bonilla, MD, Massive Bio co-founder, and chief medical officer. “Our AI-enabled technology is well positioned to optimize clinical workflows, advancing precision medicine and novel approaches to oncology research such as just-in-time, decentralized clinical trials, and digitally enabled patient-centric solutions. This recognition greatly validates our approach and current and potential impact.”

See also  eureKARE co-leads EUR 5 million seed investment in

“This recognition is a testament to the hard work of all our team and those who believe in our mission to make clinical trials accessible to all cancer patients,” added Selin Kurnaz, co-founder and CEO of Massive Bio. “We want to make sure this novel, the scalable use case of AI helps patients across the globe find personalized clinical trial options, in real-time, to treat their cancer.”

Finalists for the UCSF | Health Hub: Digital Health Awards can be introduced on October 21, with the winners revealed on the grand finale of the 2022 HLTH convention in Las Vegas on November 14.

Learn extra in regards to the UCSF | Health Hub: Digital Health Awards right here.

About Massive Bio

Founded in New York City in 2015, Massive Bio goals to offer entry to scientific trials for most cancers sufferers worldwide, no matter the place they reside or their monetary circumstances. Massive Bio solves bottlenecks in recruiting sufferers for scientific trials with a novel technology-enabled service and massive knowledge platform. The firm serves pharmaceutical firms, contract analysis organizations (CROs), and hospital networks with a give attention to bettering the lives of most cancers sufferers and offers oncology-specific, data-driven affected person recruitment, web site choice, and AI-based trial pre-screening providers.

Massive Bio was awarded an SBIR contract by the National Cancer Institute (NCI) to develop and characterize the Deep Learning Clinical Trial Matching System (DLCTMS) and is the official matching companion in all NCI-funded scientific trials. The firm can also be an energetic participant within the Integrated Trial Matching for Cancer Patients and Providers group led by MITER and the American Cancer Society Cancer Action Network.

See also  Intravenous Immunoglobulins Market Size, Share Analysis

Massive Bio has acquired investments totaling $18 million since its institution. The firm has 75 workers, companions with 26 pharmaceutical firms and CROs, and greater than 1,000 international scientific analysis facilities in 12 international locations. Massive Bio, which has reached greater than 66,000 sufferers in scientific trial matching, goals to develop that whole to 100,000 most cancers sufferers by increasing to 19 international locations with its “100K Cancer Clinical Trial Singularity Program,” introduced in 2021.

You can attain Massive Bio by way of, Twitter, LinkedIn, and Facebook.

About Arturo Loaiza-Bonilla, MD MSEd

Arturo Loaiza-Bonilla, MD, MSEd, is the co-founder and chief medical officer at Massive Bio, a world {industry} chief in connecting sufferers to scientific trials utilizing synthetic intelligence. An internationally famend medical oncologist and researcher, Dr. Loaiza-Bonilla has a distinguished tutorial and scientific profession in precision medication oncology, immunotherapy, scientific trial design, digital well being, entrepreneurship, and affected person advocacy. Dr. Bonilla is board licensed in each medical oncology and hematology, has intensive expertise within the analysis and remedy of genomic biomarker-driven cancers, and serves as enterprise Medical Director of Oncology Research at Capital Health.

Dr. Loaiza-Bonilla earned a medical diploma from the Universidad Nacional de Colombia in Bogotá, Colombia. Following medical college, he accomplished an internship and residency in inner medication at Harbor Hospital Center and Johns Hopkins Hospital in Baltimore, Maryland. Dr. Loaiza-Bonilla additionally accomplished a fellowship in hematology and oncology from the University of Miami, Miller School of Medicine in Miami, Florida. He accomplished his grasp’s diploma in medical training on the University of Pennsylvania and pursued skilled certification in Artificial Intelligence in healthcare on the MIT Sloan School of Management.

See also  Dick and Betsy DeVos Family Foundation, SoldierStrong

Before becoming a member of Capital Health, Dr. Loaiza-Bonilla was vice chairman of the Department of Medical Oncology at Cancer Treatment Centers of America in Philadelphia, Pennsylvania, in addition to enterprise director of analysis, the place he supplied management and experience to their oncology trial portfolio throughout 5 most cancers facilities and over 70 National Clinical Trials Network and industry-sponsored scientific trials. His analysis has been extensively printed in essentially the most outstanding journals and conferences in oncology, and he has been the recipient of NIH funding to advance digital well being and synthetic intelligence instruments for most cancers analysis. He was additionally an assistant professor of Clinical Medicine on the University of Pennsylvania School of Medicine and is presently an affiliate professor within the Department of Medicine at Drexel University College of Medicine, each in Philadelphia.

Merve Sahin
Massive Bio
+90 533 564 99 65
electronic mail us right here
Visit us on social media:

Source link


Please enter your comment!
Please enter your name here